Oscar Health (OSCR) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
7 Aug, 2026Executive summary
Achieved record profitability in the first half of 2026, with $1.1 billion in earnings from operations and $1 billion in net income, prompting an increase in full-year guidance.
Second quarter revenue grew 70% year-over-year to $4.88 billion, with first half revenue at $9.53 billion, driven by higher membership and rate increases.
Membership reached approximately 3.0 million as of June 30, 2026, up 46% year-over-year, reflecting strong open enrollment growth and retention.
Technology and AI initiatives drove operational efficiencies, supporting margin expansion and cost control.
Strong operating performance driven by disciplined pricing, scalable technology, and consumer-focused products.
Financial highlights
Premium revenue rose 71% to $4.79 billion for Q2 2026; investment income increased 57% to $84.8 million.
Medical loss ratio (MLR) improved to 79.2% for Q2 2026 from 91.1% in Q2 2025, aided by favorable reserve development and pricing discipline.
SG&A expense ratio hit a record low of 14.2%, a 450 basis point improvement year-over-year.
Earnings from operations were $389 million in Q2, a $619 million year-over-year increase; net income was $362 million, up $590 million.
Adjusted EBITDA reached $415 million in Q2 2026, compared to a loss of $199.4 million in Q2 2025.
Outlook and guidance
Raised full-year 2026 earnings from operations guidance to $500–$700 million, up $250 million from prior outlook.
Full-year revenue expected at $18.7–$19 billion; MLR guidance improved to 81.5%–82.5% (90 bps better at midpoint).
SG&A expense ratio guidance improved to 15.6%–16.1%; adjusted EBITDA expected to run $115 million above earnings from operations.
Management expects continued regulatory and market volatility due to changes in ACA subsidies, program integrity rules, and new tariffs on pharmaceuticals.
Outlook reflects strong first-half performance, favorable prior period development, and positive market morbidity trends.
Latest events from Oscar Health
- AI, transparency, and financial incentives are reshaping consumer-driven healthcare strategies.OSCR
7th Annual Healthcare Symposium9 Jul 2026 - Q1 2025 revenue up 42%, net income up 55%, and membership exceeded 2 million.OSCR
Q1 20259 Jul 2026 - 2025 revenue up 28% with record membership; 2026 targets profitability and margin gains.OSCR
Q4 20258 Jul 2026 - Three-year plan targets 20% revenue CAGR, 5% margin, and ICHRA-driven growth, powered by technology.OSCR
Investor Day 20248 Jul 2026 - Strong 2026 performance, favorable trends, and AI-driven integrity shape a stable outlook.OSCR
Goldman Sachs 47th Annual Global Healthcare Conference 20268 Jun 2026 - Board transitions, robust growth, and all proposals approved; no Q&A from shareholders.OSCR
AGM 20264 Jun 2026 - Revenue and net income soared, membership surged, but regulatory risks persist.OSCR
Q1 20267 May 2026 - Proxy covers director elections, say-on-pay, auditor ratification, and robust governance practices.OSCR
Proxy filing23 Apr 2026 - Votes will be cast on directors, executive pay, and auditor ratification at the June 2026 meeting.OSCR
Proxy filing23 Apr 2026